Oncology Sponsored 12 Questions with Mimi Huizinga Dr Mimi Huizinga is Vice President, Oncology Medical Affairs, Lung Cancer at AstraZeneca.
News Lynparza boosts long-term survival in early breast cancer A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.
News MSD gets first positive trial of Keytruda/Lynparza combo After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
News ASH: Regeneron plays its PNH hand Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.
News FDA clears AZ's Imfinzi for aggressive lung cancer AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
News Kelun's MSD-partnered TROP2 drug gets first okay in China Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
